About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
SKYE
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Skye Bioscience rises 10% on IRB approval for phase 2 trial for ophthalmic emulsion
- Emerald Health Therapeutics Q2 GAAP EPS of -C$0.01, revenue of C$1.28M
- Emerald Health, Skye Bioscience merger gets court approval in Canada
- Emerald Health Therapeutics GAAP EPS of -C$0.02, revenue of C$3.04M
- Emerald Health Therapeutics GAAP EPS of -C$0.19, revenue of C$11.9M
- Skye Bioscience receives Australia approval to start phase 1 study of glaucoma treatment
- Skye Bioscience to acquire Canadian cannabis company Emerald in stock deal, plans CSE listing
- Emerald Health Therapeutics sells patents to FlowerPod
- Emerald Health and HYTN Cannabis to launch cannabis beverages in Canada
- New finance chief at Skye Bioscience
- Skye Bio secures $7M capital raise, shares down 13%
- Emerald Health Therapeutics CFO Jenn Hepburn to step down
- Emerald Health Therapeutics reports Q2 results
- Skye Bioscience completes THCVHS IND-enabling in vitro genotoxicity studies
- Emerald Health Therapeutics reports Q1 results
- Emerald Health Therapeutics named ex-TerrAscend executive as COO
- Emerald Health Therapeutics reports FY results
- Emerald Health inks deal with Spanish greenhouse grower for GMP-certified cannabis
- Skye Bioscience posts preclinical data from eye disease treatment study
- Seeking Alpha Catalyst Watch